Jove
Visualize
联系我们
这页已由机器翻译。其他页面可能仍然显示为英文。View in English
  1. 首页
  3. 研究领域
  5. 生物医学和临床科学
  7. 药理学和制药科学
  9. 药物基因组学
  11. 帕金森病中的阿皮卡:一项现实世界,多中心,回顾性研究,以确定持续治疗效益的患者特征
  1. 首页
  3. 研究领域
  5. 生物医学和临床科学
  7. 药理学和制药科学
  9. 药物基因组学
  11. 帕金森病中的阿皮卡:一项现实世界,多中心,回顾性研究,以确定持续治疗效益的患者特征

相关实验视频

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
11:12

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Published on: July 16, 2014

22.6K

帕金森病中的阿皮卡:一项现实世界,多中心,回顾性研究,以确定持续治疗效益的患者特征

Clelia Pellicano1, Daniele Belvisi2,3, Roberta Bovenzi4

  • 1Laboratory of Neuropsychiatry, Santa Lucia Foundation IRCCS, Rome, Italy.

Journal of neural transmission (Vienna, Austria : 1996)
|August 31, 2025

在PubMed 上查看摘要

概括
此摘要是机器生成的。

奥皮卡是一种安全有效的治疗帕金森病 (PD) 运动波动. 实践数据显示,较年轻的运动症状患者从长期的阿片治疗中获益最多.

科学领域:

  • 神经学
  • 药理学
  • 运动障碍

背景情况:

  • 运动波动是帕金森病 (PD) 的常见并发症.
  • 作为第三代catechol- O- methyltransferase抑制剂的欧皮卡已在治疗PD运动波动方面显示出安全性和有效性.
  • 在确定持续使用阿片治疗的最佳患者情况时,实验证据至关重要.

研究的目的:

  • 在现实环境中评估阿比卡治疗的长期结果.
  • 确定与阿片安全和长期使用相关的预测因素.
  • 为了比较继续治疗的患者与停止治疗的患者的特征.

主要方法:

  • 这是一项追溯,纵向,多中心的研究,涉及178名患有PD的患者,这些患者接受了阿皮卡作为附加疗法.
  • 收集的数据包括基线和随访时的人口统计,病史,运动亚型,运动严重程度和认知/ 精神疾病.
  • 分析了继续治疗者与停止治疗者的停药率,原因和临床特征.

主要成果:

  • 85% 的患者继续接受阿皮卡治疗,平均持续时间为 30. 2 个月; 15% 的患者在 8. 9 个月内停止治疗.
  • 停药主要是由于动力障碍,低血压,胃肠道或精神问题.
  • 与停止服用的患者相比,继续服用阿皮卡的患者年轻,霍恩和雅尔分数较低,夜间OFF周期较少.
关键词:
甲基转移酶抑制剂剂量结束后的效果消失莱沃多巴动力波动关闭时间这种药物帕金森病

更多相关视频

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking
07:26

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking

Published on: September 26, 2019

8.0K
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

2.9K

相关实验视频

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
11:12

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Published on: July 16, 2014

22.6K
Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking
07:26

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking

Published on: September 26, 2019

8.0K
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

2.9K

相关概念视频

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

376
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
376
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

702
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
702
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

209
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
209
Drug Therapy01:28

Drug Therapy

96
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
96
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

结论:

  • 在现实世界帕金森病患者群体中,阿皮卡具有良好的长期耐受性和安全性.
  • 较年轻的年龄和较轻的运动严重程度与成功的长期阿片使用有关.
  • 欧皮卡治疗与PD患者的运动障碍减少和夜间休息时间减少有关.